Objective/purpose: |
Collect
supportive and pivotal data needed to establish the effectiveness
of oxytetracycline (OTC) injectable therapy to control mortality
caused by certain bacterial diseases. |
Drug name: |
Liquamycin® LA-200® |
Source of drug: |
Pfizer,
Inc. |
Address: |
Pfizer Animal Health
700 Portage Road
RIC-190-43
Kalamazoo, MI 49001-0199 |
Contact: |
Dr. Mark Subramanyam
Phone:
269-833-3388
Fax: 269-833-2707
Email: mark.subramanyam@pfizer.com |
Target
pathogen(s): |
Bacterial
pathogens susceptible to oxytetracycline. |
Method
of administration: |
IP or IM injection |
Treatment
dosage: |
20 milligrams
OTC per kilogram body weight |
Treatment
regimen: |
Option
A: Single injection (all salmonids)
Option B: Single injection (all non-salmonids) |
Withdrawal
period: |
30 days
No withdrawal
period is required for treated fish that will not be susceptible
to legal harvest for at least 30 days post-treatment. |
Required
test parameters: |
Investigator
must collect mortality data throughout the 5-day pre-treatment,
treatment, and 30-day post-treatment period. Investigator should
also report general fish behavior and any adverse effects relating
to treatment. |
Limitations
or restrictions on use: |
Investigator
must follow all instructions in the Study Protocol for INAD
9027 regarding drug acquisition and handling, fish treatment
and disposition, and data reporting requirements.
Drug
discharge must be in compliance with local NPDES permitting
requirements. |
Required
INAD fee: |
$400.00
per facility per year |
AADAP
contact for other information: |
Ms.
Bonnie Johnson, FWS - AADAP
Phone: 406-994-9905
Fax: 406-582-0242
bonnie_johnson@fws.gov |
Disclaimer: |
Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government. |
|